CTOs on the Move

Nurses Choice Corp

www.nurses-choice.com

 
Nurses Choice Corp is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Intermountain Healthcare

Intermountain Healthcare is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Intermountain Healthcare is based in Salt Lake City, UT. You can find more information on Intermountain Healthcare at www.imail.org

Prognosis Health Information Services

Prognosis Health Information Systems (PROGNOSIS) is the progeny of an eight year old hospital business software vendor and a thirty-five year old medical records service and software provider which have provided products and services to hospitals across America.

intraFUSION

intraFUSION is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enerhealth Botanicals

Improve, nourish and elevate with organic-certified mushroom coffee, vegan superfoods, herbal tinctures, cocoa, and other exceptional plant-based products.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.